IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by BIT Capital GmbH

BIT Capital GmbH lifted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 85.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 63,672 shares of the company’s stock after purchasing an additional 29,259 shares during the quarter. BIT Capital GmbH owned about 0.07% of IDEAYA Biosciences worth $1,636,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in IDYA. FMR LLC lifted its holdings in IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company’s stock worth $400,297,000 after buying an additional 1,365,570 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of IDEAYA Biosciences during the third quarter worth $42,681,000. Janus Henderson Group PLC raised its stake in shares of IDEAYA Biosciences by 26.7% in the third quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock valued at $163,518,000 after acquiring an additional 1,086,356 shares in the last quarter. State Street Corp grew its stake in IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after purchasing an additional 443,640 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company’s stock worth $130,507,000 after purchasing an additional 282,936 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analysts Set New Price Targets

IDYA has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Wedbush reiterated an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Finally, Stephens restated an “overweight” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Stock Performance

IDYA stock opened at $17.44 on Thursday. IDEAYA Biosciences, Inc. has a one year low of $16.95 and a one year high of $44.42. The company has a fifty day moving average of $21.01 and a 200-day moving average of $26.11. The stock has a market capitalization of $1.53 billion, a PE ratio of -5.28 and a beta of 0.76.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $7.00 million. Equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.